Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
First Claim
1. A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 93 wherein said polypeptide binds and activates a GLP-1 receptor.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
63 Citations
22 Claims
-
1. A polypeptide comprising the amino acid sequence of SEQ ID NO:
- 93 wherein said polypeptide binds and activates a GLP-1 receptor.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 12)
-
10. A polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs:
- 1-16, 18-59, 61-63, 65-77, 79, 81-89, and 91-92.
-
11. A pharmaceutical composition comprising a polypeptide selected from the group consisting of:
- 13. A polypeptide comprising the amino acid sequence of SEQ ID NO:
-
22. A pharmaceutical composition comprising the following structure:
Specification